587 related articles for article (PubMed ID: 25427136)
1. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
2. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
3. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
4. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
5. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
6. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
7. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Jiang YZ; Huang L; Zhou RJ; Yu KD; Liu Y; Shao ZM
Clin Cancer Res; 2013 Dec; 19(24):6853-62. PubMed ID: 24141623
[TBL] [Abstract][Full Text] [Related]
8. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
Kim S; Lee AJ; Yeo MK; Na YG; Kim JY; Cho MJ; Kim JS; Jo EK; Kim JM
Anticancer Res; 2018 Apr; 38(4):2429-2437. PubMed ID: 29599373
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Sheridan W; Scott T; Caroline S; Yvonne Z; Vanessa B; David V; Karen G; Stephen C
Breast Cancer Res Treat; 2014 Oct; 147(3):617-29. PubMed ID: 25209005
[TBL] [Abstract][Full Text] [Related]
11. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.
Ladoire S; Penault-Llorca F; Senovilla L; Dalban C; Enot D; Locher C; Prada N; Poirier-Colame V; Chaba K; Arnould L; Ghiringhelli F; Fumoleau P; Spielmann M; Delaloge S; Poillot ML; Arveux P; Goubar A; Andre F; Zitvogel L; Kroemer G
Autophagy; 2015; 11(10):1878-90. PubMed ID: 26506894
[TBL] [Abstract][Full Text] [Related]
12. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer.
Zhao H; Yang M; Zhao J; Wang J; Zhang Y; Zhang Q
Med Oncol; 2013 Mar; 30(1):475. PubMed ID: 23371253
[TBL] [Abstract][Full Text] [Related]
13. Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer.
Choi J; Jung W; Koo JS
Histopathology; 2013 Jan; 62(2):275-86. PubMed ID: 23134379
[TBL] [Abstract][Full Text] [Related]
14. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
15. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S; Marra A; Gandini S; Ascione L; Ivanova M; Venetis K; Sajjadi E; Zagami P; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Corti C; De Camilli E; Curigliano G; Fusco N; Criscitiello C
Eur J Cancer; 2023 Dec; 195():113397. PubMed ID: 37890353
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Expression of Autophagy-Related Marker (LC3B) and Stem Cell Marker (CD44) in Molecular Subtypes of Breast Cancer.
El-Deek HEM; El-Naggar MS; Sayed SG
Asian Pac J Cancer Prev; 2024 Jan; 25(1):145-152. PubMed ID: 38285778
[TBL] [Abstract][Full Text] [Related]
20. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors.
Akin D; Wang SK; Habibzadegah-Tari P; Law B; Ostrov D; Li M; Yin XM; Kim JS; Horenstein N; Dunn WA
Autophagy; 2014; 10(11):2021-35. PubMed ID: 25483883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
